| Phospho‑JAK2 (Tyr1007+Tyr1008) denotes the activated form of the non‑receptor tyrosine kinase JAK2, a member of the Janus kinase family that couples many class I and class II cytokine receptors to STAT‑dependent transcription and additional signaling cascades. The C‑terminal kinase (JH1) domain of JAK2 contains an activation loop with the tandem tyrosines Tyr1007 and Tyr1008; ligand‑induced receptor dimerization brings two JAK2 molecules into proximity, allowing trans‑autophosphorylation of these residues and a conformational rearrangement of the activation loop that converts JAK2 from a low‑activity basal state to a high‑activity catalytic state with efficient ATP utilization and robust autophosphorylation and substrate phosphorylation. Mutation of Tyr1007/Tyr1008 to nonphosphorylatable residues markedly reduces, but does not fully abolish, kinase activity, and biochemical analysis shows that activation‑loop phosphorylation is specifically required for the high‑activity state that supports full propagation of cytokine signals, while an unphosphorylated activation loop supports only a weak basal activity, indicating that Tyr1007 phosphorylation is the key determinant of catalytic up‑shift and Tyr1008 modulates this configuration. Cytokine stimulation that induces Tyr1007 phosphorylation allows JAK2 to phosphorylate receptor cytoplasmic tails and recruit SH2‑containing effectors, most prominently STAT transcription factors, which are then phosphorylated on their critical tyrosines and translocate to the nucleus to drive gene programs controlling proliferation, survival, differentiation, and inflammatory responses. Phosphorylated Tyr1007 also participates in negative regulatory pathways: activated JAK2 with a phosphorylated activation loop is preferentially recognized by the suppressor of cytokine signaling protein SOCS‑1, which targets JAK2 for polyubiquitination and proteasomal degradation, so that Tyr1007 phosphorylation both creates the high‑activity state and marks the kinase for ubiquitin‑dependent turnover, closing a feedback loop that limits signal duration. JAK2 undergoes additional phosphosite modifications in the pseudokinase and kinase domains that tune activity positively or negatively, but Tyr1007/Tyr1008 remain the central readout of catalytic activation across multiple receptor systems, including erythropoietin, thrombopoietin, growth hormone, and many interleukins, making phospho‑JAK2 (Tyr1007+Tyr1008) a widely used marker of functional engagement of the JAK2–STAT axis in hematopoietic and non‑hematopoietic tissues, and a critical node in diseases in which JAK2 signaling is dysregulated, such as myeloproliferative neoplasms and cytokine‑driven inflammatory states. |
